Currently, the biomarkers that have been identified for potential targeted therapy treatments for lung cancer are: EGFR, ALK, KRAS, MET, HER2, ROS1, BRAF, RET, NTRK1, PID3CA, MED1, VEGFR2, HER3, and IGF-1R. Of those, so far only EGFR, ALK and ROS1 have treatments approved by the FDA. However, there are many more treatments that are in clinical trials.
In this section of the Hope With Answers series, learn more about the EGFR biomarker and the most current information available regarding approved treatments for lung cancer patients with the EGFR mutation.
Hope With Answers Video Series: Biomarker EGFR
Watch Dr. Natasha Leighl of Princess Margaret Hospital in Toronto discusses the EGFR mutation in lung cancer with patient and advocate Jill Feldman. Then watch Dr. Natasha Leighl discusses more details of the EGFR mutation in lung cancer with patient and advocate Ivy Elkins.